Long-Term Open-Label Extension Study of Oral Levosimendan

Enrolling by invitation · Phase 3

Conditions studied: Pulmonary Hypertension Associated With HFpEF

In brief

The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.

Key facts

Study ID
NCT07436689
Run by
Tenax Therapeutics, Inc.
People needed
800
Starts
2026-03-13
Expected to finish
2029-03-01
Last updated by the study team
2026-07-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.